• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kyntra Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/16/26 4:05:09 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KYNB alert in real time by email
    8-K
    0000921299false00009212992026-03-162026-03-16

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 16, 2026

     

     

    KYNTRA BIO, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-36740

    77-0357827

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    350 Bay Street

    Suite 100 #6009

     

    San Francisco, California

     

    94133

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 415 978-1200

     

     

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.01 par value

     

    KYNB

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On March 16, 2026, Kyntra Bio, Inc. (“Kyntra Bio”) issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

    The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02, in Exhibit 99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Kyntra Bio, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d)

    Exhibits

    Exhibit No.

    Description

    99.1

    Press Release dated March 16, 2026

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    KYNTRA BIO, INC.

     

     

     

     

    Date:

    March 16, 2026

    By:

    /s/ David DeLucia

     

     

     

    David DeLucia
    Senior Vice President and Chief Financial Officer

     


    Get the next $KYNB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KYNB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KYNB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden to the U.S. Food and Drug AdministrationCash, cash

    3/16/26 4:02:00 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

    3/9/26 7:00:00 AM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

    FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPIHigher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trialResul

    2/23/26 5:10:00 PM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KYNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kyntra Bio Inc.

    4 - KYNTRA BIO, INC. (0000921299) (Issuer)

    3/10/26 5:41:32 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kyntra Bio Inc.

    4 - KYNTRA BIO, INC. (0000921299) (Issuer)

    3/10/26 5:40:17 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Wettig Thane

    4 - KYNTRA BIO, INC. (0000921299) (Issuer)

    2/5/26 9:08:19 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KYNB
    SEC Filings

    View All

    SEC Form 10-K filed by Kyntra Bio Inc.

    10-K - KYNTRA BIO, INC. (0000921299) (Filer)

    3/16/26 4:10:37 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KYNTRA BIO, INC. (0000921299) (Filer)

    3/16/26 4:05:09 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KYNB
    Financials

    Live finance-specific insights

    View All

    Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden to the U.S. Food and Drug AdministrationCash, cash

    3/16/26 4:02:00 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

    3/9/26 7:00:00 AM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care